Viewing Study NCT06776757

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:48 PM
Ignite Modification Date: 2026-01-04 @ 6:03 PM
Study NCT ID: NCT06776757
Status: RECRUITING
Last Update Posted: 2025-01-15
First Post: 2025-01-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Colorectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sintilimab, Cetuximab, Chemotherapy, first-line, mCRC View